The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment
Open accessAbstract
Cystic fibrosis (CF) is a genetic disease in which the battle between pulmonary infection and inflammation becomes the major cause of morbidity and mortality. We have previously shown that human MSCs (hMSCs) decrease inflammation and infection in the in vivo murine model of CF. The studies in this paper focus on the specificity of the hMSC antimicrobial effectiveness using Pseudomonas aeruginosa (gram negative bacteria) and Staphylococcus aureus (gram positive bacteria). Our studies show that hMSCs secrete bioactive molecules which are antimicrobial in vitro against Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumonia, impacting the rate of bacterial growth and transition into colony forming units regardless of the pathogen. Further, we show that the hMSCs have the capacity to enhance antibiotic sensitivity, improving the capacity to kill bacteria. We present data which suggests that the antimicrobial effectiveness is associated with the capacity to slow bacterial growth and the ability of the hMSCs to secrete the antimicrobial peptide LL‐37. Lastly, our studies demonstrate that the tissue origin of the hMSCs (bone marrow or adipose tissue derived), the presence of functional cystic fibrosis transmembrane conductance regulator (CFTR: human, Cftr: mouse) activity, and response to effector cytokines can impact both hMSC phenotype and antimicrobial potency and efficacy. These studies demonstrate, the unique capacity of the hMSCs to manage different pathogens and the significance of their phenotype in both the antimicrobial and antibiotic enhancing activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Self-citationHost Defense Peptide LL-37 Selectively Reduces Proinflammatory Macrophage Responses
Brown, K. L., Poon, G. F. T., Birkenhead, D., Pena, O. M., Falsafi, R., Dahlgren, C., Karlsson, A., Bylund, J., Hancock, R. E. W., & Johnson, P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002508 · Cited by 163
Cited by
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
Bhagirath, A. Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., & Duan, K. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0339-5 · Cited by 378
Alcayaga-Miranda, F., Cuenca, J., & Khoury, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00339 · Cited by 296
Cheng, Y., Li, L., Wang, D., Guo, Q., He, Y., Liang, T., Sun, L., Wang, X., Cheng, Y., & Zhang, G. (2017) · Stem Cells International · doi:10.1155/2017/4794827 · Cited by 48
“MSCs are currently one of the most promising candidates for cell-based targeted therapies due to their low immunogenicity, nontumourigenicity, and tumour tropism [1, 8, 27].”
BackgroundMirshekar, M., Afkhami, H., Razavi, S., Masjedian Jazi, F., Darban-Sarokhalil, D., Ohadi, E., Nezhad, M. M., & Karimi, R. (2023) · Burns · doi:10.1016/j.burns.2023.01.005 · Cited by 39
The long and winding road: stem cells for cystic fibrosis
Conese, M., Beccia, E., Castellani, S., Di Gioia, S., Colombo, C., Angiolillo, A., & Carbone, A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1413087 · Cited by 15
Metadata
- Authors
- Sutton, M. T., Fletcher, D., Ghosh, S. K., Weinberg, A., van Heeckeren, R., Kaur, S., Sadeghi, Z., Hijaz, A., Reese, J., Lazarus, H. M., Lennon, D. P., Caplan, A. I., & Bonfield, T. L.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 2016
- Issue
- 1
- Pages
- 5303048-5303048
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2292313894
- Cited by
- 171
- References
- 2
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.